All posts by U.S. Stem Cell, Inc

U.S. Department of Justice Files Lawsuit at Request of FDA to Stop U.S. Stem Cell Clinic from Performing Autologous Stem Cell Procedure

USRM Will Vigorously Defend Medical Freedom of Americans

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a world leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its intention to vigorously defend a lawsuit filed today by the U.S. Department of Justice at the request of the U.S. Food and Drug Administration (FDA).  The lawsuit seeks to stop US Stem Cell Clinic and related parties from performing a surgical procedure using stem cells from autologous adipose tissue, even when a physician and patient agree that such a procedure is in the best interest of the patient. USRM believes that the patient and physician have the right to decide whether or not to use a patient’s own cells for a therapeutic purpose without federal government interference.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead, developmental product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  

#  # #  

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

U.S. Stem Cell Reports First Quarter Results

SUNRISE, FL – May 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced first quarter results for 2018.

Revenue increased 48%, to $1.7m from $1.15m for the first quarter of 2017.  Gross profit increased more than 52%, to $1.2m from $793k for the same period last year.  Profit margin and net cash flow from operations also increased, from 55% to 71%, and $268k to $688k, respectively.

Working capital deficit is down 11%, from $5.4m at year end 2017 to $4.8m at the end of the first quarter of this year.

For two consecutive years, USRM has sustained substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.

“Our first quarter financials reflect a continued increase in market demand, as we continue to manage growth and identify ways to serve the marketplace and our business partners,” said Mike Tomas, President and Chief Executive Officer of U.S. Stem Cell, Inc.  “This is our eighth consecutive quarter of increased revenue — an indication of a possible sea change in how Americans view autologous stem cell therapy, as more and more patients seek alternatives to surgery and pharmaceuticals.”

“Our productivity continues to increase as we further our mission to help educate the public on the value of stem cell therapy, while simultaneously continuing to serve a population that is sick and tired of being sick,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc.  “Helping patients repurpose their own healing cells to employ them where their bodies need them is one of the most important scientific and holistic breakthroughs we have seen in the 21st century. We continue to be dedicated to the application of this incredible therapy to help as many people as possible.”

USRM has been instrumental in administering more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

Dr. Kristin Comella, USRM’s Chief Science Officer, continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary AdipocellTM kit to market.  Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.


U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Host Webinar on Autologous Stem Cell Therapy

MIAMI, FL – May 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,  today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar designed to inform the public about the benefits and science behind autologous stem cell therapy.

Stem Cells 101: A Patient’s Guide to Autologous Stem Cell Therapy will livestream Friday, May 11th, at twelve noon EST.  Participants who livestream the webinar may also post questions to Dr. Comella, who will answer as many livestream questions as she can during the session. “Stem Cells 101: A Patient’s Guide to Autologous Stem Cell Therapy  will also be recorded and posted following the livestream on U.S. Stem Cell’s website and in social media.

“In an era when Americans are fiercely determined to find alternatives to pain management, it’s important to understand the characteristics and science behind autologous stem cell therapy,” said Dr. Comella.  “Our goal is to inform livestreamers about key factors, such as the difference between harvesting autologous (your own) live stem cells versus utilizing a product off the shelf. Patient demand is already off the charts, but we need to provide the public with additional patient education about this emerging therapeutic and its incredible healing modality and potential, and that’s what we hope to accomplish here.”

Dr. Comella, who has more than 20+ years’ experience and is a world renowned expert in the development and clinical practice of stem cell products and therapies, is extensively published in the scientific literature in the practical application of autologous (a patient’s own) stem cell therapy.  Last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, without the risks of rejection or unknown exposure from donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to use autologous stem cell therapy for their own practices.

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

 ###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer Featured in Live Interview for Biohacker Summit in Helsinki

MIAMI, FL – May 3, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announced its Chief Science Officer, Dr. Kristin Comella, appeared live today as a featured guest for the Biohacker Summit blog — a component of the Biohacker Center in Helsinki, Finland.  Free online viewing of the live interview on stem cells is available in its entirety here.

Dr. Comella, who has more than 20+ years’ experience and is a world renowned expert in the development and clinical practice of stem cell products and therapies, is extensively published in the scientific literature in the practical application of autologous (a patient’s own) stem cell therapy.  Last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team.

AdipocellTM is USRM’s proprietary, stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in an outpatient two-hour procedure that does not require general anesthesia. Using one’s own stem cells may be a significant advantage, since rejection and other detrimental factors such as disease transmission may occur when a patient uses donated stem cells.  To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to integrate stem cells into their own practices.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales

SUNRISE, FL – April 24, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced sales figures for 2016 and 2017 for both its AdipoCellTM proprietary stem cell kit and the stem cell banking businesses — both of which demonstrate steady growth.

From 2016 to 2017, average monthly sales of AdipoCellTM increased 11%, from 209 a month to 234 a month. Sales revenue figures for first quarter 2018 are expected to be released sometime in mid May.

“The steady and significant growth in our AdipoCellTM kits is an indicator that Americans are starting to hear about the benefits of stem cell therapy, and are taking steps to augment their health or preserve their stem cells now, so that they have reserves later in life when health or aging issues may come into play,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Our increase in sales reflect the growing interest in this emerging therapy. Our operations are prepared for continued growth in 2018 in order to offer this holistic therapy to as many people as possible.”

Earlier this month, USRM opened its third partially owned standalone clinic in the United States, the newest location at The Villages in North Central Florida (the two existing clinics are in Sunrise and West Palm Beach, Florida). The Company continues to identify opportunities for clinical operations worldwide.

“Our increase in patients is providing us with an opportunity to serve the needs of more and more patients who had given up hope of improving their quality of life before considering stem cell therapy as a viable option,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We take that opportunity very seriously, and are always looking for more ways to help patients utilize their own stem cell reserves to create robust health. We look forward to identifying additional opportunities in the application of autologous stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions, and are excited about the ongoing opportunities in 2018.”

Dr. Comella, who will be speaking this week at the Paleo(X) Ancestral Healing Conference in Austin, Texas, is a world leader in stromal vascular fraction (SVF) and is a well-published trailblazer in the application of autologous stem cell therapy for a host of treatments. Since her tenure at USRM, she has performed thousands of stem cell procedures for a variety of indications.

Her experience and expertise have yielded ground-breaking results: just last month, Dr. Comella and her team were the first in the world to publish in the scientific literature in-human results of adipose stem cell therapy significantly reducing psoriasis — a condition that affects more than 7 million Americans annually. Her leadership continues to inspire other physicians who can train and certify in stem cell therapy with Dr. Comella and her team. To date, more than 700+ physicians worldwide and 288 clinics have engaged with USRM to learn how to use AdipoCellTM kits for their own practices.

AdipocellTM is a stem cell kit that enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a two-hour procedure that is generally minimally invasive and does not require general anesthesia. Using one’s own stem cells may be a significant advantage, since rejection and other detrimental factors often occur when a patient uses donated stem cells. Moreover, some of the body’s most beneficial stem cells are readily available and are stored in fat tissue, making them readily available once harvested to deploy where the body needs it most.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Announces 2017 Financial Results

SUNRISE, FL – April 16, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today filed a Form 10-K reporting year-end numbers for 2017, which reflect continued growth and increased cash flow from operations.

Revenue for 2017 increased 79% to $5.5m — up $2.4m from $3.1m in 2016.  Revenue also increased 53% in the fourth quarter of 2017 to $964k from $508k in the same quarter in 2016.  Net gross profit in 2017 increased 72% to $2.1m from $1.5m in the previous year. For the fourth quarter 2017, net gross profit was also up while overall debt decreased.

Cash flow provided from operations also increased in 2017 to $1.2m, from $112k in 2016.

USRM has sustained revenue growth for two consecutive years — from $2.2m in 2015 to $3.1m in 2016, a 41% increase; and again in 2017, with a 79% increase to $5.5m.  This sustained growth may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids. Moreover, market demand for stem cell therapy may also be increasing as a result of an improving economy, which makes out-of-pocket procedures like stem cell therapy more attainable.

“We are pleased to report our year-end results, which demonstrate we have reached a milestone in our ability to meet increasing demand for an emerging therapy in the marketplace, while simultaneously streamlining our operations,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “Marketing, finance, sales, clinical — each of our divisions is working in harmony with the other in order to attain and sustain the next level of development and growth.”

Gross profit margin decreased slightly in 2017 to 66% from 69%, due to depreciation of leased equipment.  Likewise, gross profit margin for the fourth quarter decreased from 74% to 55%, as a direct result of ramping up inventory to meet increasing demand for stem cell treatments. Increasing inventory paid off: In January 2018, USRM’s proprietary AdipoCellTM stem cell kit reached 10,000 in sales.

Operating expenses increased 36% from $3.3m in 2016 to $4.4m in 2017, primarily as a result of stock-based and other compensation.  Operating expenses also increased 14% for the fourth quarter of 2017, from $581k to $663k, primarily as a result of an increase in core operating activities.  

Loss from operations decreased 31%, or $355k, from $1.16m in 2016 to $805k in 2017. Working capital deficit is also down, 7%, from $5.8m at the end of 2016 to $5.4m at the end of 2017.  

USRM’s net loss in 2017 was $3.5m, up 68% from a net loss of $2.1m in 2016.  This increase was due to non-operating items, the largest being a $1.9m loss on change of fair value of derivative liability.  

USRM has been instrumental in performing thousands of stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

Dr. Kristin Comella, USRM’s Chief Science Officer, is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

Newest Clinic Opens Today at The Villages in Central Florida

SUNRISE, FL – April 9, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening its first USRM clinic in North Central Florida.

The U.S. Stem Cell Clinic of The Villages will offer alternatives to chronic pain management using USRM’s proprietary AdipoCell TM product in a minimally invasive procedure utilizing a patient’s own (autologous) stem cells. Medical director for the clinic will be Dr. Rosemary Daly, an interventional spine/pain management physician who is board certified in Anesthesiology and Pain Medicine. Dr. Daly, who graduated from the New York College of Osteopathic Medicine, is also medical director for the Regenerative Wellness Clinic (RWC) in West Palm Beach, which is also in the USRM network of stem cell treatment centers.

“Expansion of our regenerative healing centers to The Villages is an opportunity to directly serve an active community that is very proactive about seeking ways to increase their quality of life,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “We look forward to serving this vibrant community by offering holistic stem cell therapy for neurological, autoimmune, orthopedic and degenerative conditions.”

“Our vision at USRM has always been to expand access of autologous stem cell treatments to as many people as possible,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Now that we are seeing a steady increase in demand for stem cell therapy, which has driven our progress in reaching milestones that allow for growth, we are ready to continue expanding our network of clinics. The clinic at The Villages represents that next step.”

USRM has been instrumental in performing more than 10,000 stem cell procedures in the past 19 years for a variety of indications. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has a growing network of 288 physicians and clinics utilizing the USRM technologies, protocols and products. Dr. Comella continues to enhance USRM’s visibility worldwide for autologous stem cell treatments, as well as developing and bringing USRM’s proprietary Adipocell TM product to market: a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

Dr. Comella is also well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies. Most recently, she presented a summary of peer-reviewed publications at the Academy of Regenerative Practices Conference in Weston, Florida.

U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry
specializing in physician training and certification and stem cell products including its lead
product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation
and management of stem cell clinics. To management’s knowledge, USRM has completed more
clinical treatments than any other stem cell company in the world.

Read More

USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Stem Cells

Autoimmune Skin Condition Affects More Than 7 million in the United States

___________________________________________

SUNRISE, FL – March 21, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has published in the scientific literature that it has successfully demonstrated a 99 percent reduction in-human of the severity of psoriasis using a patient’s autologous stem cells.

The scientific paper, which is authored by USRM Chief Science Officer Dr. Kristin Comella and her USRM colleagues, is published in the International Medical Case Reports Journal, 2018:11 59-64.  

To the best of USRM management’s knowledge, this is the first result in the world published using stromal vascular fraction (SVF) and autologous stem cells in the successful treatment of psoriasis.

“This is a breakthrough for the more than 7 million Americans suffering from psoriasis, and is another example of how a patient’s own stem cells offer healing modalities for autoimmune conditions,” said Dr. Comella.  “Although we require additional studies to further develop more extensive protocol in treating patients with this condition, this is a benchmark indicating there is significant reason to believe the use of autologous stem cells is beneficial in combating this disease.”

Stromal vascular fraction (SVF) is a mixture of adipose-derived stem cells/mesenchymal stem cells, endothelial/progenitors, pericytes, fibroblasts, and other cells) obtained from a patient’s own fat tissue. Approximately 60 mL was collected under local anesthesia via a mini-lipoaspirate procedure, which was then separated from the adipocytes via centrifugation after utilizing USRM’s AdipocellTM kit to apply enzymatic digestion.

The cells were then resuspended in normal saline and injected via intravenous bolus push. The subject was monitored over a period of 12 months, and demonstrated no safety or adverse events.  The subject demonstrated a significant (99%) decrease in symptoms with a noticeable difference in skin quality appearance. Psoriasis area and severity index score went from 50.4 at baseline to 0.3 at 1 month follow-up.

Overall, the subject reported improved quality of life and willingness to continue treatments. This successful initial case study demonstrates that this may be a feasible treatment plan for patients suffering from psoriasis.

In this scientific paper, Dr. Comella et al. describe the rationale and, to their knowledge, the first clinical implementation of SVF intravenously in a patient with severe psoriasis.

“We are so proud of the work Dr. Comella and our team are doing to forge novel applications of autologous stem cells to treat a whole host of autoimmune issues,” said Mike Tomas, USRM’s Chief Executive Officer.  “What better fit for a patient than their own stem cells as a healing treatment. We look forward to continued investigation of this and other conditions to treat with autologous stem cells.”

Psoriasis is an autoimmune disease affecting 2 percent of the population worldwide and approximately 7.5 million people in the United States1. Psoriasis patients present with erythematous scaly well-defined plaques, with the scalp, knees, elbows, hands, and feet being the most commonly affected areas.2 Approximately 20% of psoriasis patients present with moderate to severe psoriasis, with more than 5% of the body surface affected. Fifteen percent of patients with psoriasis will develop psoriatic arthritis, occasionally with joint complaints such as dactylitis, sacroiliitis, enthesopathy, and spondylitis, occurring before cutaneous psoriasis. This condition can cause joint destruction due to the chronic inflammation. There are also significant comorbidities associated with psoriasis, including a 58% risk of cardiovascular disease and 43% increased risk of stroke. The risk of diabetes is 30% higher in patients with severe psoriasis.

Multipotential/Mesenchymal adult stem cells (MSCs) are currently being studied by USRM in a variety of diseases and injuries. MSCs can be found in many tissues throughout the body and are thought to play a critical role in a patient’s healing cascade. When MSCs are placed into culture or in vitro, they demonstrate an ability to differentiate on several different tissue pathways. MSCs are part of the body’s natural healing mechanism and as such represent a potential therapy in a variety of diseases, including having immunomodulatory properties and stimulating a healing response by reducing inflammation. For this reason, MSCs may be beneficial for patients experiencing excessive inflammation, as is present in autoimmune diseases like psoriasis.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.

Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S: 2003–2006 and 2009–2010 national health and nutrition examination surveys. Am J Prevent Med. 2014;47(1):37–45.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

SUNRISE, FL – March 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, is pleased to announce its Chief Science Officer, Dr. Kristin Comella, has accepted an invitation to present at the 2018 Paleo f(x) Ancestral Healing Conference Friday, April 27, at the Palmer Events Center in Austin, Texas.

Dr. Comella will present “Regenerative Medicine: The Future of Medicine is Here,” at 4:25 p.m. CST at the Kegenix Paleo On Ramp Stage.  Her presentation will be livestreamed on the USRM facebook page, follow to receive a live notification.

Dr. Comella will also participate in a Mastermind Panel entitled “Alt-Med: New Paradigms in Health and Wellness,” with several other world leaders in innovative health, including Dr. Joseph Mercola, Neurologist Dr. David Perlmutter, Naturopath Dr. Harry Adelson, epigenetic pioneer Dr. Ben Lynch and functional medicine expert Dr. Michael Ruscio, on Friday, April 27 at 5:35 p.m. CST at the ID LifeWellness Keynote Stage.  The topic will explore how traditional western medicine has been undeniably successful in battling communicable diseases and acute trauma, but how do we navigate its failure to deal with the diseases of modernity that plague us now?

“I am honored to have the opportunity to participate in the Paleo f(x) conference with such esteemed colleagues, and to share with the audience and other world innovators our latest developments on autologous stem cell therapy and stromal vascular fraction,” said Dr. Comella.  “It will be a pleasure to participate in this conference, which will feature a very interesting presence of leading health practitioners from around the world.”

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  

Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue for a more targeted application.  

In January, the Company announced AdipocellTM reached sales of 10,000+ kits worldwide.

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference

SUNRISE, FL – February 28, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, announces our participation in this year’s fourth annual Academy of Regenerative Practices’ Conference, which kicks off tomorrow and continues through March 2 & 3 at the Bonaventure Resort & Spa in Weston, Florida.

The Conference, which hosts some of the world’s leading regenerative scientists, health and medical professionals — including USRM’s Chief Science Officer & ARP President Dr. Kristin Comella — will feature more than 29 speakers including  Dr. Joseph Mercola, Dr. Josh Axe & Ben Greenfield.

The annual event also provides doctors and physicians the opportunity to receive hands-on, accredited, continuing education training in performing stem cell procedures.  Doctors are able to gain the ability to augment their practice with this cutting-edge, regenerative therapy — a process that is becoming increasingly in demand amongst the patient population in the United States suffering from neurological, autoimmune, orthopedic and degenerative conditions.

Dr. Comella will be presenting a summary of peer-reviewed publications using a stem cell procedure called Stromal Vascular Fraction (SVF), on Saturday, March 4, at 8:40 a.m.  She is well published in the scientific literature through her work at USRM on the application of stem cells and regenerative therapy, including integrating stem cells to improve knee function in cartilage damaged by osteoarthritis; a phase I clinical trial for the use of autologous stem cells in the treatment of end-stage chronic obstructive pulmonary disease; intraglandular injection of stem cells for the treatment of irradiation-induced gland damage post cancer, and the effects of the use of stem cells in patients with chronic ischemic cardiomyopathy.

Dr. Comella, who has more than 20+ years’ experience, is recognized worldwide by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s proprietary AdipocellTM product, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat, a naturally occurring tissue in the body which happens to contain a robust supply of stem cells.  Once harvested, through a minimally invasive liposuction procedure that is performed while the patient is comfortable but fully awake, the stem cells are then re-injected intravenously or applied directly to a damaged tissue or gland for a more targeted application.  

In January, the Company announced AdipocellTM reached sales of 10,000+ kits worldwide.

“It’s always such a pleasure to gather with this rapidly expanding community of scientific experts to connect and collaborate,” said Dr. Kristin Comella, USRM’s Chief Science Officer and President of the Academy of Regenerative Practices.  “This is an incredible time for regenerative medicine, and connecting with my colleagues in the scientific community who are passionate about it is always such a treat.  I look forward to another successful conference with my colleagues from around the world.”

Autologous stem cell treatments harvested from the patient’s own fat can provide healthier alternatives to the use of pharmaceuticals for treating chronic pain and degeneration.  Chronic pain has been the source of a national opioid epidemic which The New York Times reported in October is the leading cause of death for Americans under 50.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

 

Read More

USRM Posts Live Webinar with World Renowned Biohacker

Enhancing Sexual Performance with Stem Cell Therapy’ Available for Playback

SUNRISE, FL – Feb. 20, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has posted a live playback of its Saturday webinar here, “Enhancing Sexual Performance with Stem Cell Therapy —  an informative Q & A with USRM Chief Science Officer Dr. Kristin Comella and leading biohacker and CEO of health company Kion, Ben Greenfield, who recently had penile stem cell injections to enhance sexual performance.

Greenfield, who recently received stromal vascular fraction treatments (SVF) intravenously for overall bioenhancement, as well as penile injections for erectile enhancement, says as a result of the treatments his overall healing function as well as sexual performance has been significantly enhanced.

“I’ve done IV stem cells as well as knee and hip joint.  It took about 5 to 7 days to kick in.  I went from being laid up and injured to almost being 100% ready for race season,” says Greenfield, who regularly participates in Ironman and other endurance races.  Regarding autologous, IV stem cell injections, Greenfield stated “It’s a huge increase in energy… a clear head, less of a need to nap in the afternoon, better workouts and workout recovery — an improved overall sense of well-being.  With penis injection … it took about 3 to 4 days to kick in and the main things I noticed were significant increase in erectile function, a significant increase in size in what we call ‘at rest,’ better orgasms, better blood flow — the anatomical manifestations cannot be denied.”

“Ben’s experience is a perfect example of someone who is using stem cell therapy proactively, to enhance physical performance at a very high level,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “His testimony is a terrific way for patients interested in learning more about the process to get a front row seat, even in the playback the questions and answers can be beneficial for those who are interested in the process.”

SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.

Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy.  The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live Feb. 9, can be accessed as a playback here.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

CEO Blog: February 2018

Dear Shareholders and Friends,

Thank you all so much for taking the time to learn more about our recent progress.  In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.

A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.  

We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily.  Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.

We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases.  We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.

The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice.  Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.   

USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential.  We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients.  We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.

Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases.  As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace.   We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time.  We are confident that timing is now.

USRM technologies are now offered in six continents with interest from various countries throughout the world growing.  We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles.  These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them.  We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.

The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain.  Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population.  Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells.  Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.  Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.  

Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform.   Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants.  Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.

In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield.  The webinar, which is entitled Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance.  Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine.  He was successful at increasing both size and rate of performance.  To listen to that webinar in its entirety click here.

Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology.  We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.

Warmest regards,

Mike Tomas,

President and CEO

Read More

USRM CSO to Host Live Stem Cell Info Webinar with World Renowned Biohacker

‘Discussing Enhancing Sexual Performance with Stem Cell Therapy’ Feb. 17 at Noon

SUNRISE, FL – Feb. 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield — a leading biohacker and fitness expert and CEO of health company Kion— who recently had penile stem cell injections to enhance sexual performance.

Enhancing Sexual Performance with Stem Cell Therapy,” will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST.  To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689.

Greenfield, a self-professed ‘biohacker’ who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.  

“My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”

“Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it’s Valentine’s Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “Ben’s experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them.”

SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.

Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy.  The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live last Friday, can be accessed as a playback here.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Successfully Launches Stem Cell Webinar Series

Open to Global Participation, More than 100 Attendees in First Q & A

SUNRISE, FL – Feb. 12, 2018 – Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.

Facts About Stem Cell Therapy,” which had its first live broadcast last Friday and includes a question & answer session from more than 100 patients and physicians around the world, continued for nearly two hours while live streamers posted questions to Dr. Comella about the application of autologous stem cells therapy.   Such a strong, positive response demonstrates the growing demand for information about this emerging, holistic, regenerative therapy.

Playback of the webinar can be accessed here:

http://www.brainshark.com/Stemlogix/vu?pi=zHEz136Dfmz5OLvz0.

Dr. Comella will be hosting a second livestream webinar Saturday, Feb. 17, at 12 noon EST (Click here to register).  In honor of Valentine’s Day and the month of love, her featured guest will be fitness expert Ben Greenfield, who recently underwent stem cell therapy for erectile enhancement — a multi-million-dollar industry that is increasing in patient population but is underserved, mainly due to side effects associated with erectile dysfunction pharmaceuticals currently on the market.

“The webinar platform gives us the perfect opportunity to make the concept of autologous stem cell therapy accessible to the world,” said Dr. Comella.  “It also enables audience participation in a manner that allows for privacy.  I read the questions to the audience, so we maintain privacy from the inquisitor while simultaneously providing the opportunity for a comprehensive teaching moment, even in playback.  It’s a perfect way to help people learn more about this incredible form of healing.”  

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

“Dr. Comella is a natural — her passion is contagious and her expertise in stem cell therapy is unparalleled,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “Because demand has been so strong at our clinics, as more and more people are learning about stem cell therapy as an alternative to pain management, the webinar format gives us the opportunity to reach more people faster, and to meet the demand for more specific information in a really efficient and effective way.”

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More

USRM Seeing Explosive Increase in Demand for Stem Cell Therapy

Failure of Opioids & Economic Growth Driving Force,

CSO to Host Live Info Webinar

SUNRISE, FL – Feb. 6, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.

As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells,” will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.

“Our phones are ringing off the hook,” said Dr. Comella.  “Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain.  Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments,” said Dr. Comella.

Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.

“We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product,” said Tomas.  “We believe this is an indicator of continued growth to come.”

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, can be seen in The Healing Miracle docuseries here.  To view Dr. Comella’s interview online, click the link and fill out the information, which will provide complimentary access.

To access Dr. Comella’s live webinar this Friday, Feb. 9, at Noon EST, click here to register or join.  Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company’s website and its Facebook page (https://www.facebook.com/USStemCellInc/).

USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Read More